Mangoceuticals, Inc. (MGRX)
NASDAQ: MGRX · Real-Time Price · USD
0.3728
+0.0158 (4.43%)
Jun 8, 2026, 11:17 AM EDT - Market open
Mangoceuticals Revenue
Mangoceuticals had revenue of $67.86K in the quarter ending March 31, 2026, a decrease of -37.91%. This brings the company's revenue in the last twelve months to $414.58K, down -18.88% year-over-year. In the year 2025, Mangoceuticals had annual revenue of $456.02K, down -25.96%.
Revenue (ttm)
$414.58K
Revenue Growth
-18.88%
P/S Ratio
14.78
Revenue / Employee
$138,193
Employees
3
Market Cap
6.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 456.02K | -159.85K | -25.96% |
| Dec 31, 2024 | 615.87K | -115.62K | -15.81% |
| Dec 31, 2023 | 731.49K | 722.55K | 8,083.16% |
| Dec 31, 2022 | 8.94K | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CareCloud | 124.14M |
| OptimizeRx | 107.35M |
| DarioHealth | 21.19M |
| Healthcare Triangle | 20.04M |
| VSee Health | 14.46M |
| Zhongchao | 11.37M |
| Mobile-health Network Solutions | 7.32M |
| OneMedNet | 1.32M |
MGRX News
- 20 days ago - Mangoceuticals Quarterly report: Q1 2026 - Filings
- 2 months ago - Mangoceuticals Annual report: Q4 2025 - Filings
- 2 months ago - Why Is Mangoceuticals, Inc. Stock (MGRX) Up Today? - TipRanks
- 2 months ago - Mangoceuticals files civil lawsuit against Clarity Ventures - TheFly
- 2 months ago - Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc. - GlobeNewsWire
- 3 months ago - Mangoceuticals announces patent filing for MGX-0024 - TheFly
- 3 months ago - Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds - GlobeNewsWire
- 3 months ago - Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study - GlobeNewsWire